MGMT and central nervous system cancer: The cohort had several clinical and molecular characteristics: age ≥ 80 years (26.4%), lower-grade glioma (18.6%), preoperative KPS scores below 70 (51.4%), resection (34.3%), adjuvant RT + TMZ (68.6%), MGMT promoter methylation (48.6%), IDH1/2 mutation (7.7%) and TERT promoter mutation (60.9%).